An observational study in PARKINSON DISEASE (Disorder), Physical Activity and Sedentary Behaviors, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Karolinska Institutet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Parkinson Disease by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Karolinska Institutet.
Among the 10 studies in Parkinson Disease by Karolinska Institutet, this one is the only one that started in 2026, is one of 4 observational ones, and was the 9th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →3 of the 10 studies in Parkinson Disease by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Karolinska Institutet · Sites in Sweden
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 450 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 106 across the 6 interventional studies, 292 across the 4 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
1 of the studies in Parkinson Disease by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06901869Karolinska InstitutetPhysical Activity in Persons With Parkinson's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Parkinson Disease by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to identify why some people with Parkinson's disease (PwPD) become less physically active, and which factors support or hinder activity. Understanding these factors is essential for developing person centred interventions and effective support that can be implemented in routine healthcare. A national, multicentre longitudinal cohort study will be conducted including approx 450 PwPD from five Swedish regions (including the internal pilot NCT06901869). Physical activity will be measured objectively with activity monitors, combined with clinical assessments and digital questionnaires over four years. The primary outcome is physical activity level (accelerometer measured decline), and exposure variables include physical, cognitive, disease specific, social, environmental, motivational, and personal factors. Data collection involves clinical tests, questionnaires, accelerometer data, and patient reported experiences.
This is a continuation of an internal pilot study NCT06901869. The study will enable early identification of those at risk for declining activity and guide development of person centred, evidence based interventions. Long term, it aims to integrate activity monitoring and risk factor screening into routine care to improve health and quality of life for PwPD.
People with Parkinson's disease with mild to severe severity (Hoehn \& Yahr 1-4) of all ages
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention
Physical activity - low and moderate intensity
The primary outcome is changes over time in PA (i.e. low + moderate-vigorous intensity PA in time spent per day) measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Time frame: Baseline and yearly follow-ups for 3 years
Physical activity - total vector magnitude
The secondary outcomes are change over time in total vector magnitude measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Time frame: Baseline and yearly follow-ups for 3 years
Physical activity - low intensity
The secondary outcomes are change in time spent in low intensity physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Time frame: Baseline and yearly follow-ups for 3 years
Physical activity - moderate high intensity
The secondary outcomes are change in time spent in moderate-vigorous physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Time frame: Baseline and yearly follow-ups for 3 years
Physical activity- sedentary
The secondary outcomes are change in sedentary time per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Time frame: Baseline and yearly follow-ups for 3 years
Physical activity - steps
The secondary outcomes are change in steps per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Time frame: Baseline and yearly follow-ups for 3 years
Disease severity, Parkinsons symptoms
Disease severity measured with the Movement Disorders Society -Unified Parkinson's Disease Rating Scale) parts 1 to 4. Higher scores = worse/more symptoms
Time frame: Baseline and 3 year follow-up
Gait
Gait speed in m/s measured with the 10 meter walking test or through gait analysis.
Time frame: Baseline and 3 year follow-up
Balance performance
Assessed with the Mini-BESTest. Mini-Balance Evaluation Systems Test a rating scale for dynamic balance incorporating 14 different balance and gait items that were assessed by a physical therapist on a scale from 0-2. 0-28 points with higher scores indicating better balance control
Time frame: Baseline and 3 year follow-up
Anxiety and depression
Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better
Time frame: Baseline and yearly follow-ups for 3 years
Cognitive performance
Assessed with the Montreal Cognitive Assessment (MoCA), 0-25, higher score = better
Time frame: Baseline and 3 year follow-up
Motivation
Assessed with the Behavioural Regulation in Exercise Questionnaire (BREQ 4), a 28-item survey that measures exercise motivation. The questionnaire uses a 7-point Likert scale, ranging from one to seven. Maximum 196. Higher scores = higher motivation
Time frame: Baseline and yearly follow-ups for 3 years
Self-efficacy
Assessed with the Self-efficacy and motivation for exercise/physical activity (ESES). 10 questions rated on a 4 point Likert scale. Maximun 40 points, higher scores= better self-efficacy
Time frame: Baseline and yearly follow-ups for 3 years
Physical activity history and preferences,
Self-made questions on physical activity history and preferences
Time frame: Baseline
Self assessed cognitive function
Assessed with Executive function questionnaire (DEX), 20 items scored 1 to 4, max 80, more scores= worse
Time frame: Baseline and yearly follow-ups for 3 years
Non-Motor Symptoms
Non-Motor Symptoms Questionnaire (NMSQ), 30 questions with yes/no answer. More yes answers = more non-motor symptoms
Time frame: Baseline and yearly follow-ups for 3 years
Walking ability- self rated
WALK-12G questionnaire, 0 and 42 points, with higher scores reflecting greater perceived walking difficulties (higher=worse)
Time frame: Baseline and yearly follow-ups for 3 years
Freezing of gait - self-assessed
Freezing of gait questionnaire (FOGQsa), 6 questions/items, scored 1 to 5 (higher=worse)
Time frame: Baseline and 3 year follow-up
Balance confidence
Activities specific balance confidence (ABC scale), 16 items which is scored 1 to 10 and then divided by 16. 0-100%, higher % = better
Time frame: Baseline and yearly follow-ups for 3 years
Fatigue
Parkinson's Fatigue Scale (PFS-16), 16 items scored 1 to 5 from strongly disagree to strongly agree . more points/score= worse.
Time frame: Baseline and yearly follow-ups for 3 years
Disability
World health organization (WHO) disability assessment schedule (Whodas 2.0), 12 self-assessed questions (12 to 60) more points=worse
Time frame: Baseline and 3 year follow-up
Sleep
Scales for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP), 4 parts, A-2 questions, B-5 questions , C-1 question and D- 6 questions. Higher= worse
Time frame: Baseline and 3 year follow-up
Self-rated pain
Assessed with visual analog scale, VAS from 0 to 100
Time frame: Baseline and yearly follow-ups for 3 years
Health related quality of life
Parkinson's Disease Questionnaire (PDQ39). The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communications and bodily discomfort). The sum score is as a percentage score ranging between 0 and 100. Higher is better
Time frame: Baseline and yearly follow-ups for 3 years
Wellbeing
The WHO- Five Well-Being Index (WHO-5), 5 questions ranging from 0 to 5, 0-25, higher=better
Time frame: Baseline and yearly follow-ups for 3 years
Nutrition
Mini Nutritional Assessment, max 14. higher = better
Time frame: Baseline and 3 year follow-up
Socioeconomic status
Education and income level.
Time frame: Baseline
Plan to share: Yes — The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient, provided that the recipient has an approved ethics application.
Supporting information: Statistical analysis plan
Time frame: We plan to share this when applicable on OSF or similar
Access criteria: The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2030, 59 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 59 months is above that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.